Skip to main content
Pharmafile

Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?

Autumn 2019
Authors
Maria Isabel ManleyDr. Chris Boyle

Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.

View Article

Contacts

Manley, Maria Isabel
合伙人律师
Boyle, Chris
合伙人律师

Capabilities

Suggested News & Insights

Growth Meets Guardrails: Getting You Ready for the New Realm of Ad/PromoWednesday, May 13, 2026
活动
Sidley Represents Archimed in US$1.1 Billion Acquisition of Esperion TherapeuticsMay 1, 2026
公告
Most-Favored-Nation Drug Pricing Policy: Executive Actions, Manufacturer Agreements, and Growing Congressional ScrutinyApril 22, 2026
Global Life Sciences Update
Sidley Represents Opus Genetics in US$155 Million Financing With Oberland CapitalApril 21, 2026
公告
Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement FinancingApril 21, 2026
公告
U.S. FDA Issues First Drug Supply Chain Security Act Warning Letter Targeting a Dispenser, Signaling Expanded Enforcement FocusApril 15, 2026
Food, Drug, and Medical Device Update